• Sodium Orthovanadate: Mechanism and Evidence Boundaries

  2026-10-19

  Sodium Orthovanadate (Na3VO4) is described by APExBIO as a reversible, competitive inhibitor of protein tyrosine phosphatases, alkaline phosphatase, and ATPase enzymes. Its principal interpretive value is as a phosphatase-inhibitory measurement tool, but the same breadth of activity limits attribution of phosphorylation or metabolic readouts to upstream kinase signaling alone.

• PP 3: Identity, Control Role, and Evidence Limits

  2026-10-17

  PP 3 is identified by APExBIO as 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine and a negative control for the Src kinase inhibitor PP 2. The available product information supports a catalog-level identity and intended comparator role, but provides no identity-matched study, target-binding data, kinase panel, cellular readouts, effect sizes, or independent evidence establishing PP 3 as biologically inactive or mechanistically selective.

• Sodium Orthovanadate: Identity, Mechanism, and Scope

  2026-10-16

  Sodium Orthovanadate (Na3VO4) is described by APExBIO as a broad, reversible inhibitor of protein tyrosine phosphatases and several other phosphatase, ATPase, and metabolic enzyme classes. The product information supports a conceptual role in phosphorylation state preservation, but it does not establish potency, selectivity, cellular performance, or study-specific outcomes.

• High Yield T7 Biotin16 RNA: Evidence Boundaries

  2026-10-16

  The APExBIO product page identifies the High Yield T7 Biotin16 RNA Labeling Kit, SKU K1082, but supplies no product description, matched publication, performance dataset, or comparative study. Its name supports a cautious, conceptual interpretation involving T7-associated RNA synthesis and biotin-mediated detection or capture; it does not establish formulation, labeling density, yield, transcript quality, or application-specific performance.

• Cy3 NHS Ester: Identity, Mechanism and Evidence

  2026-10-15

  APExBIO identifies Cy3 NHS ester (non-sulfonated), SKU A8100, as an amine-reactive cyanine fluorophore for labeling proteins, peptides, and oligonucleotides. Its reported optical properties support orange fluorescence detection, but the available evidence is product documentation rather than an identity-matched research study, so it does not establish labeling efficiency, biological imaging performance, or clinical utility.

• MG-262: Mechanism, Evidence, and Scope

  2026-10-15

  MG-262, also identified as Z-Leu-Leu-Leu-B(OH)2, is described by APExBIO as a reversible, cell-permeable boronic peptide acid that inhibits proteasome chymotryptic activity. The available product information supports a conceptual interpretation of proteasome inhibition, ubiquitinated-protein accumulation, and reported downstream cellular effects, but it does not provide an identity-matched primary study, quantitative outcomes, or independent validation of the stated applications.

• NVP-BGJ398 Phosphate: Evidence and Scope

  2026-10-14

  APExBIO describes NVP-BGJ398 phosphate, or BGJ-398 phosphate, as a selective pan-FGFR1–3 inhibitor that acts by suppressing FGFR autophosphorylation and downstream ERK1/2 signaling. The available evidence is limited to supplier-reported biochemical, cellular, xenograft, and development-status claims; no identity-matched primary research paper or detailed outcome statistics are available for independent verification.

• SUMO Protease (Ulp): Identity and Evidence Scope

  2026-10-14

  APExBIO’s K1103 is described as a recombinant yeast Ulp1-derived cysteine protease intended for conceptual SUMO fusion-tag removal. The available evidence supports product identity and intended use, but not independent performance, comparative efficacy, or target-specific applicability.

• Anti-DYKDDDDK Magnetic Beads: Evidence Scope

  2026-10-13

  APExBIO’s K4207 is documented as a magnetic affinity-bead product bearing anti-Flag M2 monoclonal antibodies for conceptual capture of DYKDDDDK (Flag)-tagged proteins. The supplied evidence supports product identity and intended applications, but no matched peer-reviewed study is available to independently verify performance, binding capacity, reusability, or applicability across sample types.

• Tropisetron Hydrochloride: Evidence and Boundaries

  2026-10-13

  Tropisetron Hydrochloride is described as a 5-HT3 receptor antagonist with additional α7-nicotinic receptor activity. In a 2021 cell-based study, tropisetron inhibited OCT2- and MATE1-associated transport, supporting a mechanistic basis for studying renal drug-transporter interactions. These findings remain preclinical and do not establish clinical interaction risk or generalize to every cationic drug.

• Cas13d Control and the TEV Protease Boundary

  2026-10-12

  Zhu et al. report stimulus-responsive RfxCas13d variants created through domain insertion at an allosteric site, enabling light- or rapamycin-analog-dependent RNA knockdown. The study supports engineered allostery as a route to temporal control, but it does not evaluate TEV Protease, recombinant protein tag removal, or whether purification-related modifications preserve Cas13d activity.

• PP 1 and the Evidence Around Src-Kinase Signaling

  2026-10-12

  PP 1 is described by APExBIO as a Src family tyrosine kinase inhibitor, whereas the supplied atrial-fibrillation study implicates C-terminal Src kinase (CSK) in an off-target effect of ibrutinib. These findings provide useful mechanistic context but do not establish PP 1 as a model of ibrutinib-associated atrial fibrillation or as evidence for clinical effects.

• Protease Inhibitor Cocktail EDTA-Free: Evidence Overview

  2026-10-10

  This overview examines the research context, conceptual applications, and evidence boundaries of an EDTA-free protease inhibitor cocktail. It distinguishes supplier-reported formulation claims from published findings and explains why the supplied poultry study does not independently validate protease-inhibition performance.

• Sulforaphane, Oxidative Stress, and NLRP3 in Colitis

  2026-10-09

  A 2024 mouse study links sulforaphane-mediated reduction of oxidative stress with suppression of NLRP3 inflammasome signaling in experimental colitis. Its combined animal and macrophage evidence strengthens a mechanistic hypothesis for inflammatory bowel disease research, while remaining preclinical and model-dependent.

• H 89 2HCl in PKA Signaling Research

  2026-10-09

  H 89 2HCl is widely used as a pharmacological probe of cAMP-dependent protein kinase activity, but supplier-reported selectivity does not eliminate cellular off-target concerns. This overview compares its biochemical and cellular evidence with a recent Neuroligin 1–D2-MSN study, which implicates PKC rather than PKA in repetitive behavior phenotypes.

664 records 1/45 page Next 12345 下5页 Last page